

Jean-Jacques Grob

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2714178/jean-jacques-grob-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86
papers

20,771
citations

43
h-index

97
g-index

97
ext. papers

26,683
ext. citations

11.3
avg, IF

6.12
L-index

#	Paper	IF	Citations
86	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101601	2.2	10
85	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.. <i>European Journal of Cancer</i> , 2022 , 163, 79-87	7.5	0
84	Prognostic and predictive value of Tblockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. <i>European Journal of Cancer</i> , 2022 , 165, 97-112	7.5	0
83	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	4.0	18
82	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. <i>Blood</i> , 2021 , 138, 790-790	2.2	1
81	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
80	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. <i>European Journal of Cancer</i> , 2021 , 156 Suppl 1, S23-S24	7.5	1
79	Reply to E. Hindi <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2	
78	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. <i>Annals of Oncology</i> , 2021 , 32, 542-551	10.3	2
77	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. <i>Journal of Translational Medicine</i> , 2021 , 19, 142	8.5	1
76	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 655-664	21.7	9
75	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 643-654	21.7	58
74	Not all melanomas are created equal: a review and call for more research into nodular melanoma. <i>British Journal of Dermatology</i> , 2021 , 185, 700-710	4	2
73	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study 2021 , 9,		9
72	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1119-1132	4.6	3
71	Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire. <i>Quality of Life Research</i> , 2021 , 30, 1225-1231	3.7	2
70	Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2149-2153	4.6	3

69	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 2021 , 9,		7
68	Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1949-1956	4.6	3
67	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. <i>European Journal of Cancer</i> , 2021 , 154, 57-65	7.5	4
66	Which adjuvant treatment for patients with BRAF-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021 , 148, 145-155	0.3	2
65	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020 , 133, 94-103	7.5	8
64	Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy. <i>European Journal of Cancer</i> , 2020 , 135, 52-61	7.5	7
63	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020 , 8,		19
62	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020 , 13, 457-467	3.7	3
61	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020 , 128, 60-82	7.5	60
60	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020 , 128, 83-102	7.5	76
59	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. <i>European Journal of Cancer</i> , 2020 , 126, 141-158	7.5	63
58	Anti-N-methyl-D-aspartate receptor encephalitis during treatment with adalimumab for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e591-e593	4.6	1
57	SARS-CoV-2 infection presenting as a febrile rash. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e304-e306	4.6	52
56	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. <i>European Journal of Cancer</i> , 2020 , 126, 159-177	7.5	81
55	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 519-527	13.4	148
54	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020 , 16, 4429-4438	3.6	23
53	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020 , 4, 5203-5214	7.8	6
52	Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1465-1477	21.7	140

51	The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2183-2197	4.6	10
50	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3925-3936	2.2	78
49	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
48	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology, The</i> , 2019 , 20, 1083-1097	21.7	356
47	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019 , 116, 148-157	7.5	42
46	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology. <i>European Journal of Cancer</i> , 2019 , 112, 29-31	7.5	12
45	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 119, 1-10	7.5	79
44	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1239-1251	21.7	425
43	Diabetes and Blood Glucose Disorders Under Anti-PD1. <i>Journal of Immunotherapy</i> , 2018 , 41, 232-240	5	17
42	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1789-1801	59.2	918
41	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e180077	13.4	214
40	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018 , 78, 1197-1209	2.1	23
39	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 916-929	21.7	83
38	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>European Journal of Dermatology</i> , 2018 , 28, 775-783	0.8	11
37	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1480-1492	21.7	680
36	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017 , 28, 1631-1639	10.3	361
35	Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. <i>Annals of Oncology</i> , 2017 , 28, 1137-1144	10.3	53
34	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017 , 82, 45-55	7.5	114

33	Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 863-873	21.7	389
32	Macrophage activation syndrome: A new complication of checkpoint inhibitors. <i>European Journal of Cancer</i> , 2017 , 77, 88-89	7.5	19
31	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1824-1835	59.2	1178
30	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
29	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017 , 390, 1853-1862	40	703
28	Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. <i>European Journal of Cancer</i> , 2017 , 84, 44-54	7.5	55
27	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. <i>ESMO Open</i> , 2017 , 2, e000203	6	11
26	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017 , 136, 2085-2087	16.7	230
25	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. <i>JAMA Oncology</i> , 2017 , 3, 1511-1519	13.4	101
24	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
23	Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision. <i>PLoS ONE</i> , 2017 , 12, e0176080	3.7	4
22	Risk factors of fast growing melanomas in a French prospective cohort.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21042-e21042	2.2	
21	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016 , 27, 1947-53	10.3	18
20	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology, The</i> , 2016 , 17, 1743-1754	21.7	205
19	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 1845-1855	59.2	870
18	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
17	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15003	51.1	283
16	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 522-30	21.7	842

15	Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1191-6	2.2	334
14	Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 67-75	4.3	203
13	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	4.0	926
12	Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. <i>European Journal of Cancer</i> , 2014 , 50, 1120-4	7.5	11
11	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. <i>Annals of Oncology</i> , 2014 , 25, 1428-1436	10.3	36
10	On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. <i>Annals of Oncology</i> , 2014 , 25, 2086-2091	10.3	64
9	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014 , 120, 2016-24	6.4	15
8	On-demand Gamma Knife combined with BRAF inhibitors for the treatment of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9083-9083	2.2	
7	Evidence of a limited intra-individual diversity of nevi: intuitive perception of dominant clusters is a crucial step in the analysis of nevi by dermatologists. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 2355-2361	4.3	13
6	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2012 , 380, 358-65	4.0	2233
5	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>New England Journal of Medicine</i> , 2011 , 364, 2517-26	59.2	3396
4	Cognitive training with photographs as a new concept in an education campaign for self-detection of melanoma: a pilot study in the community. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1099-103	4.6	8
3	Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: a randomized study. <i>International Journal of Cancer</i> , 2006 , 118, 2276-80	7.5	60
2	Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 65, 809-16	4	77
1	Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1118-25	2.2	374